Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 03, 2023

Tepotinib Treatment for MET Exon 14–Skipping NSCLC

JAMA Oncology


Additional Info

JAMA Oncology
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2023 Jun 04;[EPub Ahead of Print], J Mazieres, PK Paik, MC Garassino, X Le, H Sakai, R Veillon, EF Smit, AB Cortot, J Raskin, S Viteri, YL Wu, JCH Yang, MJ Ahn, R Ma, J Zhao, A O'Brate, K Berghoff, R Bruns, G Otto, A Johne, E Felip, M Thomas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading